ECM
OVID icon

Endurant Capital Management’s Ovid Therapeutics OVID Stock Holding History

Endurant Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-116,297
Closed -$347K – 69
2020
Q1 		$347K Buy
+116,297
New +$392K 0.16% 49

Other funds holding OVID

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Endurant Capital Management's OVID Position: Q2 2020 in Review

Endurant Capital Management sold out of Ovid Therapeutics (OVID) in Q2 2020, closing a stake of 116,297 shares — an estimated $347K sold.

Endurant Capital Management first reported a position in OVID in Q1 2020 and held it in 1 quarter. The position peaked at $347K in Q1 2020. 79 funds tracked by Wall St. Rank hold OVID as of Q2 2020.

  • Endurant Capital Management reported no remaining Ovid Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Endurant Capital Management sold 116,297 Ovid Therapeutics shares in Q2 2020, an estimated $347K.
  • Endurant Capital Management first reported a position in Ovid Therapeutics in Q1 2020 and held it in 1 quarter.
  • Endurant Capital Management's Ovid Therapeutics position peaked at $347K in Q1 2020.
  • 79 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2020.

Based on Endurant Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.